A Phase 1 Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2019
Price : $35 *
At a glance
- Drugs Gilteritinib (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Astellas Pharma
- 25 Sep 2019 Planned End Date changed from 1 Aug 2021 to 1 Jun 2021.
- 25 Sep 2019 Planned primary completion date changed from 1 Jan 2020 to 1 Jun 2021.
- 22 Mar 2019 Planned number of patients changed from 70 to 75.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History